All Stories

  1. Pre-infusion quantitative EEG features associated with delayed neurocognitive impairment following CAR T-cell therapy
  2. Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort
  3. Implementación del Código Crisis para la atención urgente de la epilepsia en España: un protocolo asistencial integral
  4. Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice
  5. Safranal-Standardized Saffron Extract Improves Metabolic, Cognitive, and Anxiolytic Outcomes in Aged Mice via Hypothalamic–Amygdalar Peptide Modulation
  6. Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour
  7. Long-term Impact of Cenobamate on Cognition in Patients with Drug-Resistant Focal Epilepsy: Outcomes from an Exploratory Real-World Study
  8. Prior restraint stress counteracts memory deficits associated with adolescent alcohol exposure by targeting both the hippocampal endocannabinoid and glutamatergic systems
  9. Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer’s Disease
  10. Late-onset Rasmussen encephalitis: 3 illustrative cases and a review of the literature
  11. Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV‐add study
  12. Cataract Surgery in Cognitive Impairment: Navigating the Accessibility Challenge in European Healthcare
  13. Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)
  14. Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer’s disease detection
  15. Relapses in Anti-NMDAR Encephalitis
  16. Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies
  17. Proposal of an Inflammatory Drug‐Resistant Epilepsy Index (Idrei) as Molecular Composed Biomarker in Focal Epilepsies
  18. Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis
  19. Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy
  20. Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease
  21. Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy
  22. Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology
  23. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  24. Pronóstico funcional de pacientes con NORSE y FIRES tratados con inmunoterapia: revisión sistemática
  25. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis
  26. Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis
  27. Biomarkers of Neuroinflammation and Epileptogenesis: A Systematic Review
  28. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats
  29. Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus
  30. Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder
  31. Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus
  32. Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions
  33. Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study
  34. Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition
  35. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study
  36. Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol
  37. Encefalopatía epiléptica y del desarrollo asociada a mutación del SYNGAP1: descripción de un caso y respuesta al tratamiento con cannabidiol
  38. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
  39. Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies
  40. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  41. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  42. Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
  43. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis
  44. Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
  45. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
  46. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  47. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy
  48. Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review
  49. Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis
  50. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  51. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  52. Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
  53. The cognitive and psychiatric subacute impairment in severe Covid-19
  54. Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido probar otro?
  55. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
  56. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  57. Prevalence of Neural Autoantibodies in Paired Serum and Cerebrospinal Fluid in Adult Patients with Drug-Resistant Temporal Lobe Epilepsy of Unknown Etiology
  58. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)
  59. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  60. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
  61. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain
  62. Efectos de la pandemia por Covid-19 sobre la calidad de vida de los pacientes con Esclerosis Lateral Amiotrófica
  63. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  64. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis
  65. GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus
  66. Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis
  67. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  68. Emergency implementation of telemedicine for epilepsy in Spain: Results of a survey during SARS-CoV-2 pandemic
  69. Miller‐Fisher syndrome after SARS‐CoV‐2 infection
  70. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases
  71. Reader response: Neurologic complications of coronavirus infections
  72. Ofatumumab versus Teriflunomide in Multiple Sclerosis
  73. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report
  74. Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2
  75. Análisis de letalidad por COVID-19 en pacientes con demencia neurodegenerativa
  76. Incidence and case fatality rate of COVID-19 in patients with active epilepsy
  77. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?
  78. ¿Va a cambiar la neurología tras la pandemia de COVID-19 en los próximos 5 años? Estudio de enfoque mediante informadores clave
  79. Response to immunotherapy in anti‐IgLON5 disease: A systematic review
  80. Evaluación prequirúrgica mediante resonancia magnética funcional en pacientes con tumores neuroepiteliales disembrioplásicos: una serie de casos
  81. Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit
  82. Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene
  83. Miastenia grave inducida por tratamiento con inhibidores del punto de control inmunológico: primer caso secundario a avelumab y revisión de casos previamente publicados
  84. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN
  85. Consenso Delphi EPICON: recomendaciones sobre el manejo adecuado del cambio a acetato de eslicarbazepina en epilepsia
  86. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review
  87. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures
  88. Estudio observacional multicéntrico español sobre el empleo de fármacos antiepilépticos en consultas de neurología
  89. Epidemiología de la epilepsia en España y Latinoamérica
  90. Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients
  91. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
  92. Awagrafia
  93. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
  94. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa
  95. Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study
  96. Adhesión al tratamiento con levetiracetam: estudio observacional retrospectivo no intervencionista
  97. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
  98. Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature
  99. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
  100. Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study
  101. Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015
  102. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study
  103. Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study
  104. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide
  105. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
  106. Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness
  107. Spatial recognition memory in a virtual reality task is altered in refractory temporal lobe epilepsy
  108. The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES)
  109. Validación en castellano de un cuestionario breve útil para cribado epidemiológico de epilepsia en España: Cuestionario EPIBERIA
  110. Acetato de eslicarbazepina en la práctica clínica. Resultados de eficacia y seguridad
  111. Zonisamida en el tratamiento de la epilepsia: revisión de la bibliografía desde la terapia añadida a la monoterapia
  112. Consenso de las Recomendaciones de Actuación diagnóstica y Terapéutica sobre Epilepsia resistente a fármacos antiepilépticos en España (Consenso RATE-España)
  113. Predictive model for refractoriness in Temporal Lobe Epilepsy based on clinical and diagnostic test data
  114. Cajal’s first steps in scientific research
  115. Spatial navigation impairment in patients with refractory temporal lobe epilepsy: Evidence from a new virtual reality-based task
  116. Factores vinculados a la adhesión al tratamiento en pacientes con epilepsia refractaria y no refractaria
  117. Antiepileptic treatment in patients with epilepsy and other comorbidities
  118. Vohwinkel Syndrome secondary to missense mutation D66H in GJB2 gene (connexin 26) can include epileptic manifestations
  119. Amnesia topográfica transitoria: descripción de una serie de ocho casos
  120. Possible case of peripheral osmotic demyelination syndrome
  121. Driving cost factors in adult outpatients with refractory epilepsy: A daily clinical practice in clinics of neurology in Spain
  122. Guía de práctica clínica de la Sociedad Andaluza de Epilepsia sobre profilaxis y tratamiento de las crisis epilépticas sintomáticas agudas
  123. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia sobre prescripción de fármacos antiepilépticos genéricos
  124. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia: recomendaciones terapéuticas ante una crisis epiléptica y en el estado epiléptico
  125. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia para el diagnóstico y tratamiento del paciente con una primera crisis epiléptica en situaciones de urgencia
  126. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)
  127. Possible case of peripheral osmotic demyelination syndrome
  128. Incidencia de ictus en España. Bases metodológicas del estudio Iberictus
  129. Pseudomigraña con pleocitosis y la ‘invisibilidad’ de las descripciones originales en castellano
  130. Clinical Implications of Mechanisms of Resistance to Antiepileptic Drugs
  131. Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS
  132. Bilateral Bell Palsy and Acute HIV Type 1 Infection: Report of 2 Cases and Review
  133. Menstrual Tension-Type Headache: Evidence for Its Existence.
  134. A transcranial doppler study in interictal migraine and tension-type headache
  135. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  136. Encefalomielitis aguda diseminada por picadura de himenóptero
  137. Avances en el conocimiento de la etiología y la fisiopatología de las epilepsias reflejas
  138. Cirugía de la epilepsia del lóbulo temporal: ¿es suficiente eliminar las crisis?
  139. Trombólisis en el ictus: la accesibilidad sin garantía de seguridad es insostenible
  140. Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'
  141. The Red Ear Syndrome: Five New Cases
  142. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica antiepiléptica crónica en el adulto y en el niño
  143. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: III. Tratamiento antiepiléptico en situaciones especiales
  144. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: I. Criterios de inicio y cese y bases farmacológicas del tratamiento antiepiléptico
  145. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: IV. Principios generales de politerapia antiepiléptica y estrategias terapéuticas en epilepsia refractaria
  146. Doppler transcraneal en el diagnóstico de fístula arteriovenosa pulmonar
  147. Infarto maligno de la arteria cerebral media: ¿tratamiento médico o quirúrgico?
  148. Hemorragia cerebral múltiple y antiagregantes plaquetarios
  149. Ring chromosome 20 epilepsy syndrome in children: Electroclinical features
  150. Paciente de 45 años con epilepsia refractaria del lóbulo temporal desde la infancia
  151. Epilepsia refractaria del adulto
  152. Comment: Fluorouracil-Induced Aphasia: Neurotoxicity versus Cerebral Ischemia
  153. Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia
  154. Epilepsia parcial refractaria a tratamiento médico y lesión porencefálica occipital
  155. Controversias en torno a los nuevos fármacos antiepilépticos
  156. El diagnóstico de la enfermedad cervical espondilótica: una revisión basada en la evidencia
  157. Caracterización epidemiológica de la epilepsia del adulto subsidiaria de ingreso hospitalario
  158. Pseudotumor inflamatorio: diagnóstico diferencial de los tumores del IV ventrículo
  159. Cromosoma 20 en anillo: ¿Una canalopatía epiléptica?
  160. Ischemic Stroke following Cisplatin and 5-Fluorouracil Therapy: A Transcranial Doppler Study
  161. Descripción histórica de la asociación de macroorquídia, retraso mental y dismorfia craneal en varones (Síndrome del cromosoma X frágil) por A. B. Richerand
  162. Hemodinámica cerebral en el síndrome de pseudomigraña con pleocitosis de LCR: un estudio Doppler transcraneal
  163. El diagnóstico de la esclerosis temporal mesial mediante imagen de resonancia magnética
  164. Correlación genotipo-fenotipo en la distrofia miotónica y predicción de la gravedad clínica
  165. Hemiatrofia facial progresiva de Parry-Romberg: consideraciones patogénicas y evolutivas a propósito de un caso con seguimiento prolongado
  166. Esclerosis temporal mesial (II): manifestaciones clínicas y estudios complementarios
  167. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases
  168. Mediterranean spotted fever with central and peripheral neurological complications